PDA TR 82 fundamentally changed the paradigm from "Does the test pass?" to "Does the test remain valid throughout the shelf-life of the sample?" Conclusion: Why You Must Read PDA TR 82 If you work in Quality Control, Process Development, or Regulatory Affairs for sterile injectable drugs, PDA Technical Report 82 is not optional reading—it is essential.
In response, the PDA formed a dedicated task force. This group, composed of experts from regulatory bodies (including the FDA), major pharma companies (Amgen, Genentech, Pfizer), and reagent manufacturers (Lonza, Charles River), worked for over four years to standardize the understanding of LER. Their work culminated in (2018).
Review all marketed and pipeline parenteral products. Flag any containing polysorbates (20 or 80), Cremophor, cyclodextrins, or EDTA. pda technical report 82
The report demystifies a complex colloidal phenomenon and provides a practical, risk-based framework to protect patients from masked endotoxin. It acknowledges that no test is perfect, but through aggressive investigation and mitigation, we can close the safety gap.
Enter , titled "Low Endotoxin Recovery" . Published by the Parenteral Drug Association (PDA) in 2018, this document is the most authoritative, comprehensive resource for understanding, investigating, and mitigating LER. This article provides a deep dive into TR 82, its findings, methodologies, and its impact on the biopharmaceutical industry. Part 1: The Problem – What is Low Endotoxin Recovery (LER)? Before discussing the solution, one must understand the problem. LER refers to the inability to recover detectable endotoxin activity from a sample matrix even though endotoxin has been intentionally spiked into that matrix. PDA TR 82 fundamentally changed the paradigm from
For years, LER was a poorly understood anomaly where endotoxin activity appeared to diminish or "disappear" in certain drug product matrices over time, even though the endotoxin was physically present. This created a regulatory blind spot, as standard QC testing could produce false negatives.
Furthermore, the industry is moving toward . Instead of just testing the final product, manufacturers are using real-time bioburden monitoring and endotoxin removal chromatography to eliminate LER risk at the source. Their work culminated in (2018)
In the world of parenteral drug manufacturing, ensuring sterility and safety is paramount. While the compendial bacterial endotoxins test (BET), often regulated by USP <85> and EP 2.6.14, has been the gold standard for decades, the industry has faced a perplexing and potentially dangerous phenomenon: Low Endotoxin Recovery (LER) .